Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline

By Reuters News


Overview

  • US biopharmaceutical company reported Q3 net loss narrowed from prior year period

  • Q3 operating expenses fell due to lower clinical trial and legal costs

  • Company announced contingent value rights tied to potential future priority review voucher monetization


Outlook

  • Atossa expects FDA IND clearance for (Z)-endoxifen in MAS and DMD by early 2027

  • Company expects topline data from Phase 2 EVANGELINE study in Q2 2027

  • Select data from I-SPY2 study to be presented at SABCS in December 2026


Result Drivers

  • LOWER CLINICAL TRIAL SPEND - Co said decline in clinical trial expenses was due to completion of enrollment in (Z)-endoxifen studies

  • LOWER LEGAL FEES - Co attributed reduced G&A expenses to lower legal fees following resolution of patent litigation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.56

Q3 Net Loss

$5.64 mln

Q3 Operating Expenses

$5.9 mln

Q3 Operating Income

-$5.9 mln

Q3 Pretax Loss

$5.64 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Atossa Therapeutics Inc is $22.00, about 932.9% above its November 9 closing price of $2.13


Reuters Recommended Reads

  • Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses

  • Nov 9 - Perspective Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 10 - PMV Pharmaceuticals Q3 net loss widens on warrant charges


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk